Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients

Summary

To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.

Timeline

Start

2015-04-02

Primary completion

2016-06-16

Completion

2016-09-06

Outcome

Missed primary endpoint

registry p = 0.0644; Difference of LS mean change -4.9 (95% CI -10.2 to 0.3); ANCOVA NCT02396316 ↗

Publications

• Rittiphairoj T, Roberti G, Michelessi M. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2023 Apr 3;4(4):CD007920. doi: 10.1002/14651858.CD007920.pub4.
• Inatani M, Higashide T, Matsushita K, Miki A, Ueki M, Iwamoto Y, Kobayashi M, Leal S; VEGA Investigators. Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial. Adv Ther. 2021 Feb;38(2):1116-1129. doi: 10.1007/s12325-020-01579-5. Epub 2020 Dec 16.

Drugs

Indications